Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
Go back to Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting| (NASDAQ: IONS) | Delayed: 56.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.71 | 52 Week High | $62.68 | |||
| Open | $56.71 | 52 Week Low | $19.59 | |||
| Day High | $56.71 | P/E | N/A | |||
| Day Low | $56.71 | EPS | $0.00 | |||
| Volume | 665 | |||||
